{
    "clinical_study": {
        "@rank": "43701", 
        "acronym": "PACE", 
        "arm_group": [
            {
                "arm_group_label": "Exercise", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "Control group asked to continue usual activities"
            }
        ], 
        "brief_summary": {
            "textblock": "The general objective of the study is to investigate the effect of regular aerobic exercise\n      on resting and 24-hr blood pressure levels in men and women with stage 3-4 kidney disease\n      and hypertension."
        }, 
        "brief_title": "Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Focus Chronic Kidney Disease With Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Non-diabetic and >18 years of age\n\n               -  Diagnosed kidney disease with associated hypertension:\n\n               -  Non-nephrotic range proteinuria at diagnosis\n\n               -  No active glomerular disease or concomitant systemic inflammatory disease (e.g.\n                  lupus)\n\n               -  Systolic blood pressure >130 and/or diastolic blood pressure >80 mm Hg (on\n                  medication)\n\n               -  An estimated glomerular filtration rate of between 60 ml/min and 15 ml/min.\n\n               -  Individuals must be able to provide informed consent\n\n               -  Perform walking exercise training on a treadmill\n\n               -  Be able to participate in a 12-week supervised exercise program.\n\n        Exclusion Criteria:\n\n          -  Currently participating in a formal exercise program\n\n          -  Diabetes, active glomerular disease, or systemic inflammatory disease\n\n          -  Requiring dialysis\n\n          -  Have an Hematocrit <27%\n\n          -  Uncontrolled hypertension (>200/110mmHg)\n\n          -  Peripheral vascular disease.\n\n          -  An inability to understand English or give consent. Other exclusion criteria are: any\n             contraindications to exercise testing or training as indicated by the American\n             College of Sports Medicine guidelines such as: Unstable coronary heart disease and\n             symptomatic heart failure, exercise capacity limited by health problems such as\n             angina, severe arthritis, or extreme dyspnea on exertion, progressive neuromuscular\n             disease, pulmonary disease, or having undergone a coronary revascularization within\n             the past 6 months prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112825", 
            "org_study_id": "1207M17821", 
            "secondary_id": "R03DK097318"
        }, 
        "intervention": {
            "arm_group_label": "Exercise", 
            "description": "Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes", 
            "intervention_name": "Exercise", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Exercise", 
            "blood pressure", 
            "chronic kidney disease"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "brona001@umn.edu", 
                "last_name": "Ulf G Bronas, PhD", 
                "phone": "612-625-9308"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Ulf G Bronas, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease", 
        "overall_contact": {
            "email": "brona001@umn.edu", 
            "last_name": "Ulf G Bronas, PhD", 
            "phone": "612-625-9308"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Ulf G Bronas, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "resting and 24-hour ambulatory blood pressure", 
            "measure": "blood pressure", 
            "safety_issue": "No", 
            "time_frame": "at week 0 and at week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112825"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "investigator_full_name": "Ulf G. Bronas", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Pulse wave velocity estimated systemic vascular resistance", 
                "measure": "effective vascular compliance", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "description": "measured by brachial artery flow mediated vasodilation", 
                "measure": "endothelial function", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "description": "Circulating levels of angiotensin 2 Circulating levels of endothelin 1 asymmetric dimethylarginine", 
                "measure": "biomarkers associated with blood pressure", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }
        ], 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}